natgillin/translations-raw huggingface dataset:
Please tell your doctor or nurse if you are taking or have recently taken any other medicines. 
Povejte zdravniku ali medicinski sestri, če jemljete ali ste pred kratkim jemali katero koli drugo zdravilo.
If you are pregnant or planning to become pregnant or think you may be pregnant If you are not using effective contraception (see Pregnancy, contraception and breast-feeding). 
• če ste noseči, načrtujete nosečnost ali menite, da bi lahko bili noseči, • če ne uporabljate učinkovite kontracepcije (glejte Nosečnost, kontracepcija in dojenje),
• congenital choroid plexus cyst; 
• kongenitalne ciste horoidnega pleksusa,
PHARMACEUTICAL FORM AND CONTENTS 50 film-coated tablets. 
FARMACEVTSKA OBLIKA IN VSEBINA 50 filmsko obloženih tablet.
Other problems such as: weight loss, gout, high blood sugar, bleeding, bruising. 
Druge težave, kot so: • izguba telesne mase, protin, visok krvni sladkor, krvavitve, modrice.
The most serious gastrointestinal disorders were ulceration and hemorrhage which are known risks associated with mycophenolate mofetil. 
Najresnejše bolezni prebavil so bile razjede in krvavitve, ki so znana tveganja, povezana z mofetilmikofenolatom.
Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome. 
Zdravila CellCept zato ne dajemo bolnikom z redkim dednim pomanjkanjem hipoksantin-gvanin-fosforibozil-transferaze (HGPRT), kot sta Lesch-Nyhlanov in Kelley-Seegmillerjev sindrom.
As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of CellCept is correlated with MPA concentration. 
Kot je razvidno iz supresije akutne zavrnitvene reakcije po transplantaciji ledvice, je imunosupresivno delovanje zdravila CellCept povezano s koncentracijo mikofenolne kisline.
The MAH shall ensure that in each MS where Cellcept is marketed, all healthcare professionals and patients who are expected to prescribe, dispense or use Cellcept are provided with the following educational package: · Physician educational material · Patient information pack 
Imetnik dovoljenja za promet mora zagotoviti, da v vseh državah članicah, kjer je zdravilo CellCept na tržišču, vsi zdravstveni delavci in bolniki, za katere se pričakuje, da bodo predpisovali, izdajali ali uporabljali zdravilo CellCept, prejeli naslednja izobraževalna gradiva:
As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking CellCept. 
Kot previdnostni ukrep je za vas ali vašo partnerko priporočljivo, da med zdravljenjem in 90 dni po končanem zdravljenju uporabljate/uporablja zanesljivo obliko kontracepcije.
The most serious infections were sepsis, peritonitis, meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. 
Najbolj resne okužbe so bile sepsa, peritonitis, meningitis, endokarditis, tuberkuloza in atipična mikobakterijska okužba.
PHARMACEUTICAL FORM AND CONTENTS 100 Capsules 
FARMACEVTSKA OBLIKA IN VSEBINA 100 kapsul
CellCept contains sorbitol (a type of sugar). 
• Zdravilo CellCept vsebuje sorbitol (vrsta sladkorja).
PHARMACEUTICAL FORM AND CONTENTS Multipack:150 (3 packs of 50) film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA Skupno pakiranje: 150 (3 škatle po 50) filmsko obloženih tablet
• You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner's syndrome or uterine agenesis 
• ste se rodili z eno od naslednjih redkih stanj, zaradi katerih nosečnost ni mogoča: genotip XY,
Because of robust clinical evidence showing a high risk of abortion and congenital malformations when mycophenolate mofetil is used in pregnancy every effort to avoid pregnancy during treatment should be taken. 
Zaradi zanesljivih kliničnih dokazov, ki kažejo na visoko tveganje za splav in kongenitalne malformacije, če se mofetilmikofenolat uporablja v nosečnosti, je treba poskrbeti za ukrepe, ki preprečijo nosečnost med zdravljenjem.
CellCept is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. 
Zdravilo CellCept je zaviralec inozin-monofosfat-dehidrogenaze (IMPDH).
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 - 6 months post-transplant). 
V zgodnjem obdobju po presaditvi (do 40. dneva po presaditvi) je srednja AUC mikofenolne kisline pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom za približno 30 % manjša, Cmax pa za približno 40 % manjša v primerjavi s poznejšim obdobjem po presaditvi (3 do 6 mesecev po presaditvi).
(The shelf-life of the reconstituted suspension is two months.) 
(Rok uporabnosti pripravljene suspenzije je dva meseca.)
Birth defects which have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed). 
Okvare ob rojstvu, o katerih so poročali, vključujejo nepravilnosti ušes, oči, obraza (razcep ustnice ali neba), razvoja prstov, srca, požiralnika (cevi, ki povezuje žrelo z želodcem), ledvic in živčnega sistema (na primer spino bifido (kjer kosti hrbtenice niso pravilno razvite)).
There is evidence of a higher frequency of certain types of infections (see section 4.4). 
Zabeležili so tudi višjo incidenco določenih vrst okužb (glejte poglavje 4.4).
What CellCept is and what it is used for 
Kaj je zdravilo CellCept in za kaj ga uporabljamo 2.
Following reconstitution to a concentration of 6 mg/mL, CellCept 500 mg powder for concentrate for solution for infusion must be administered by slow intravenous infusion over a period of 2 hours by either a peripheral or a central vein (see section 6.6). 
Po pripravi raztopine v koncentraciji 6 mg/ml CellCept 500 mg praška za koncentrat za raztopino za infundiranje jo je treba dajati s počasno intravensko infuzijo vsaj 2 uri bodisi v periferno ali centralno veno (glejte poglavje 6.6).
This leaflet was last revised on {MM/YYYY} Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu 
Navodilo je bilo nazadnje revidirano {MM/LLLL} Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Add about half of the total amount of purified water to the bottle. 
Polovico prečiščene vode dajte v steklenico.
• isavuconazole - used to treat fungal infections 
• izavukonazol - uporablja se za zdravljenje glivičnih okužb,
CellCept 500 mg powder for concentrate for solution for infusion is an alternative dosage form to CellCept oral forms (capsules, tablets and powder for oral suspension) that may be administered for up to 14 days. 
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje je alternativna odmerna oblika peroralnim oblikam zdravila CellCept (kapsule, tablete in prašek za peroralno suspenzijo), ki jo lahko bolnik prejema do 14 dni.
Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures only by small margins such that the risk of genotoxic effects on sperm cells cannot completely be excluded. 
Mofetilmikofenolat je bil v študijah na živalih pri koncentracijah, ki le v majhni meri presegajo terapevtske izpostavljenosti pri človeku, genotoksičen in tako tveganja za genotoksične učinke na spermije ne moremo popolnoma izključiti.
• Nervous system malformations such as spina bifida; 
• malformacije živčnega sistema, kot je spina bifida
Pregnancy, puerperium and perinatal conditions Cases of spontaneous abortions have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6. 
Motnje v času nosečnosti, puerperija in v perinatalnem obdobju Poročali so o primerih spontanih splavov pri bolnicah, izpostavljenih mofetilmikofenolatu, pretežno v prvem trimesečju, glejte poglavje 4.6.
LIST OF EXCIPIENTS Also contains aspartame (E951) and methyl parahydroxybenzoate (E218). 
SEZNAM POMOŽNIH SNOVI Med pomožnimi snovmi sta tudi aspartam (E951) in metilparahidroksibenzoat (E218).
Other medicines and CellCept 
Druga zdravila in zdravilo CellCept
An estimated total of 1268 patients received CellCept during four clinical trials in the prevention of acute organ rejection. 
Ocenili so, da je zdravilo CellCept prejemalo skupno 1268 bolnikov v štirih kliničnih preskušanjih preprečevanja akutne zavrnitve presajenega organa.
Turn the whole thing back round the right way. 
Steklenico in razdelilnik skupaj obrnite pravilno nazaj.
If you are planning to become pregnant or if you get pregnant while you or your partner are taking CellCept. 
• če nameravate zanositi ali zanosite v času, ko vi ali vaš partner jemlje zdravilo CellCept.
In renal transplant patients with severe chronic renal impairment (glomerular filtration rate < 25 mL/min/1.73 m2), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. 
Bolnikom s hudo kronično ledvično okvaro (glomerulna filtracija < 25 ml/min/1,73 m2) izven obdobja neposredno po presaditvi ne dajemo odmerkov, večjih od 1 g dvakrat na dan.
Take 2 tablets in the morning and then 2 tablets in the evening. 
• Vzemite 2 tableti zjutraj in 2 tableti zvečer.
• CellCept should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. 
• Zdravila Cellcept ne smemo uporabljati pri bolnikih s preobčutljivostjo za mofetilmikofenolat, mikofenolno kislino ali katero koli pomožno snov, navedeno v poglavju 6.1.
CellCept has a moderate influence on the ability to drive and use machines. 
Zdravilo CellCept ima zmeren vpliv na sposobnost vožnje in upravljanja strojev.
* contains phenylalanine equivalent to 2.78 mg/5 mL of suspension. 
* Vsebuje 2,78 mg fenilalanina v 5 ml suspenzije.
PRCA may resolve with dose reduction or cessation of CellCept therapy. 
PRCA je lahko reverzibilna z zmanjšanjem odmerka ali s prekinitvijo zdravljenja z zdravilom CellCept.
• fluid on the lungs or inside the chest, 
• tekočina v pljučih ali prsih,
• Take 7.5 mL suspension in the morning and then 7.5 mL suspension in the evening. 
• Vzemite 7,5 ml suspenzije zjutraj in 7,5 ml suspenzije zvečer.
Take care not to let any powder from inside a broken capsule get into your eyes or mouth. 
Bodite previdni, da prašek, ki ga vsebujejo poškodovane kapsule, ne pride v oči ali usta.
An estimated total of 1557 patients received CellCept during five clinical trials in the prevention of acute organ rejection. 
Ocenili so, da je zdravilo CellCept prejemalo skupno 1557 bolnikov v petih kliničnih preskušanjih preprečevanja akutne zavrnitve presajenega organa.
CellCept tablets: lavender coloured caplet-shaped tablet, engraved with "CellCept 500" on one side and "ROCHE" name on the other. 
CellCept tablete: svetlo vijoličaste barve, ovalne oblike, z vgraviranim napisom “CellCept 500” na eni strani in imenom “ROCHE” na drugi.
What you need to know before you take CellCept 
Kaj morate vedeti, preden boste vzeli zdravilo CellCept
METHOD OF ADMINISTRATION For intravenous infusion only Read the package leaflet before use 
POSTOPEK UPORABE Samo za intravensko infuzijo Pred uporabo preberite priloženo navodilo
• If you are allergic (hypersensitive) to mycophenolate mofetil, mycophenolic acid or any of the other ingredients in this medicine (listed in Section 6) 
• če ste alergični (preobčutljivi) na mofetilmikofenolat, mikofenolno kislino, polisorbat 80 ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in the elderly patients (≥ 65 years) when compared to younger patients. 
Ugotovili so, da farmakokinetika mofetilmikofenolata in njegovih presnovkov pri starejših bolnikih (≥ 65 let) s presadki v primerjavi z mlajšimi bolniki s presadki ni spremenjena.
1 carton contains 100 capsules (in blister packs of 10) 1 carton contains 300 capsules (in blister packs of 10) 
1 škatla s 100 kapsulami (v pretisnih omotih po 10 kapsul) 1 škatla s 300 kapsulami (v pretisnih omotih po 10 kapsul)
The shelf-life of the powder for oral suspension is 2 years. 
Rok uporabnosti praška za peroralno suspenzijo je 2 leti.
Patients should be advised that during treatment with CellCept, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). 
Bolnike, ki prejemajo zdravilo CellCept, moramo opozoriti, da so lahko cepiva manj učinkovita, uporabi živih cepiv pa se morajo izogibati (glejte poglavje 4.5).
A bottle adapter and 2 oral dispensers are also provided. 
V ovojnini sta dodana tudi nastavek za steklenico in 2 peroralna razdelilnika.
OTHER SPECIAL WARNING(S), IF NECESSARY CellCept film-coated tablets should be handled with care Do not crush the tablets 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA CellCept filmsko obložene tablete je treba uporabljati previdno Tablet ne drobite
Cardiac transplant n = 289 
Presaditev srca n = 289
• septum pellucidum agenesis; 
• agenezija septuma pelluciduma,
What CellCept looks like and contents of the pack 
Izgled zdravila CellCept in vsebina pakiranja
Take 3 tablets in the morning and then 3 tablets in the evening. 
• Vzemite 3 tablete zjutraj in 3 tablete zvečer.
Counselling of patients: This section will emphasise the importance of a thorough, informative and ongoing dialogue between patient and healthcare professional about the pregnancy risks associated with mycophenolate mofetil and the relevant minimisation strategies including alternative treatment choices, if applicable. 
To poglavje bo poudarilo pomembnost temeljitega, poučnega in stalnega pogovora med bolnikom in zdravstvenim delavcem o tveganju uporabe mofetilmikofenolata med nosečnostjo in ustreznih strategijah za njegovo zmanjševanje, vključno z drugimi možnostmi zdravljenja, če so primerne.
• They are available as packs of 50 (in blister packs of 10) or Multipacks containing 150 (3 packs of 50) tablets. 
• Na voljo so v pakiranjih s 50 (pretisni omoti po 10) ali v skupnih pakiranjih s 150 (3 škatle po
CellCept is used to prevent your body rejecting a transplanted organ. 
Zdravilo CellCept prepreči, da bi vaše telo zavrnilo presadek.
Patients treated with immunosuppressants, including CellCept, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). 
Bolniki, ki se zdravijo z imunosupresivi, vključno z zdravilom CellCept, imajo povečano tveganje za oportunistične okužbe (bakterijske, glivične, virusne in protozojske), smrtne okužbe in sepso (glejte poglavje 4.8).
• If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription as mycophenolate causes birth defects and miscarriage. 
• če ste bolnica, ki bi lahko bila noseča, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mofetilmikofenolat povzroči prirojene okvare in spontani splav,
A detailed description of the preparation is given below: 
Podroben opis priprave je podan spodaj: Korak 1
As can happen in patients taking this type of medicine (immune-suppressants), a very small number of CellCept patients have developed cancer of the lymphoid tissues and skin. 
Kot se lahko zgodi pri bolnikih, ki jemljejo takšno vrsto zdravil (zdravila za zaviranje imunske odzivnosti), se je pri zelo majhnem številu bolnikov, ki so jemali zdravilo CellCept, pojavil rak limfatičnih tkiv in kože.
When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between CellCept patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen. 
Ko so primerjali deleže zavrnitve presadka, deleže izgube presadka ali profile neželenih učinkov med bolniki, zdravljenimi z zdravilom CellCept v kombinaciji s telmisartanom ali brez njega, niso opazili nobenih kliničnih posledic farmakokinetičnega medsebojnega delovanja med zdraviloma.
even if their symptoms are the same as yours 
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
If you are allergic (hypersensitive) to mycophenolate mofetil, mycophenolic acid or any of the other ingredients in this medicine (listed in Section 6) If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage. 
Ne jemljite zdravila CellCept: • če ste alergični (preobčutljivi) na mofetilmikofenolat, mikofenolno kislino ali katero koli sestavino tega zdravila (navedeno v poglavju 6), • če ste bolnica, ki bi lahko bila noseča, in pred prvim predpisanim receptom nimate potrjenega negativnega testa nosečnosti, saj lahko mofetilmikofenolat povzroči prirojene okvare in spontani splav,
If you need to have a vaccine (a live vaccine) while taking CellCept, talk to your doctor or pharmacist first. 
Če se morate cepiti (z živim cepivom), medtem ko jemljete zdravilo CellCept, se prej pogovorite z zdravnikom ali farmacevtom.
In addition, a pregnancy follow-up questionnaire including details of exposure during pregnancy, including timing and dose; duration of therapy, before and during pregnancy; concomitant drugs; known teratogenic risks and full details of congenital malformations should be agreed to with the national competent authorities. 
Dodatno se je treba z nacionalnim organom, pristojnim za zdravila, dogovoriti o vprašalniku o spremljanju nosečnosti, ki bo vseboval podrobnosti o izpostavitvi med nosečnostjo, času in odmerku, trajanju zdravljenja pred in med nosečnostjo, sočasno uporabljenih zdravilih, znanih tveganjih za teratogenost in vsemi podrobnostmi o kongenitalnih malformacijah.
CellCept 500 mg powder for concentrate for solution for infusion must be prepared in two steps: the first step is a reconstitution step with glucose intravenous infusion 5% and the second step is a dilution step with glucose intravenous infusion 5%. 
Zdravilo CellCept 500 mg prašek za koncentrat za raztopino za infundiranje moramo pripraviti v dveh korakih: prvi korak je rekonstitucija z intravensko infuzijo 5-% glukoze, drugi korak pa je razredčitev z intravensko infuzijo 5-% glukoze.
This data support extrapolation of this finding to all antacids because the reduction in exposure when CellCept was coadministered with magnesium and aluminium hydroxides is considerably less than when CellCept was co-administered with PPIs. 
Ti podatki podpirajo ekstrapolacijo teh ugotovitev na vse antacide, saj je zmanjšanje izpostavljenosti, kadar je zdravilo CellCept sočasno uporabljeno z magnezijevimi in aluminijevi hidroksidi, občutno manjše v primerjavi s sočasno uporabo zdravila CellCept in zaviralcev protonske črpalke.
It is recommended that the suspension be reconstituted by the pharmacist prior to dispensing to the patient 
Priporočljivo je, da suspenzijo pred izdajo zdravila bolniku pripravi farmacevt Pred uporabo preberite priloženo navodilo
Add the remainder of water and shake the closed bottle well for about 1 minute. 
Dodajte preostalo količino vode in temeljito stresajte zaprto steklenico približno 1 minuto.
Agranulocytosis and neutropenia have been reported; therefore, regular monitoring of patients taking CellCept is advised (see section 4.4). 
Poročali so tudi o agranulocitozi in nevtropeniji, zato je priporočljivo bolnike, ki prejemajo zdravilo CellCept, redno spremljati (glejte poglavje 4.4).
Hypersensitivity reactions to CellCept have been observed (see section 4.8). 
Opazili so preobčutljivostne reakcije na zdravilo CellCept (glejte poglavje 4.8).
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with CellCept and CsA compared with patients receiving sirolimus or belatacept and similar doses of CellCept (see also section 4.4). 
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30-50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z zdravilom CellCept in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke zdravila CellCept (glejte tudi poglavje 4.4).
These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle), headache, flu symptoms and swelling. 
Ti vključujejo resne alergijske reakcije (kot sta anafilaksa, angioedem), povišano telesno temperaturo, utrujenost, motnje spanca, bolečine (bolečino v želodcu, bolečino v prsih, bolečino v sklepih ali mišicah), glavobol, gripi podobne simptome in otekline.
What CellCept is and what it is used for What you need to know before you take CellCept How to take CellCept 
Kaj je zdravilo CellCept in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo CellCept Kako jemati zdravilo CellCept Možni neželeni učinki
Muscular weakness 
mišična šibkost
If neutropenia develops (absolute neutrophil count < 1.3 x 103/µl), it may be appropriate to interrupt or discontinue CellCept. 
Če se pojavi nevtropenija (absolutno število nevtrofilcev < 1,3 x 103/μl), moramo zdravljenje z zdravilom CellCept prekiniti ali opustiti.
Do this by: wearing protective clothing which also covers your head, neck, arms and legs using a sunscreen with a high protection factor. 
• uporabljate zaščitna oblačila, ki pokrijejo tudi vašo glavo, vrat, roke in noge,
Patients on CellCept who develop recurrent infections should have their serum immunoglobulins measured. 
Bolnikom, ki jemljejo zdravilo CellCept in se jim okužbe ponavljajo, je treba določiti raven imunoglobulinov v serumu.
Adverse reactions attributable to peripheral venous infusion were phlebitis and thrombosis, both observed at 4% in patients treated with CellCept 500 mg powder for concentrate for solution for infusion. 
Neželena učinka, ki ju lahko pripišemo periferni venski infuziji, sta bila flebitis in tromboza, ki so ju opazili pri 4 % bolnikov, zdravljenih z zdravilom CellCept 500 mg prašek za koncentrat za raztopino za infundiranje.
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous infusion only Reconstitute and dilute before use Read the package leaflet before use 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Samo za intravensko infuzijo Pred uporabo rekonstituirajte in razredčite Pred uporabo preberite priloženo navodilo
Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. 
Običajne težave Pogostejše težave so driska, zmanjšano število belih ali rdečih krvničk v krvi, okužbe in bruhanje.
Take off the child safety bottle cap and push the bottle adapter into the neck of the bottle. 
Odstranite za otroke varno zaporko in v vrat steklenice potisnite nastavek za steklenico.
The first dose is given to you as soon as possible after the transplant operation. 
• Prvi odmerek boste prejeli čimprej po presaditvenem posegu.
These are insufficient to make dosage recommendations, and therefore use in this age group is not recommended. 
Ti so nezadostni za navodila o priporočenem odmerjanju, zato uporaba zdravila CellCept v tej starostni skupini ni priporočljiva.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
Ime in naslov proizvajalca, odgovornega za sproščanje serij
Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, CellCept tablets should not be crushed. 
Ker ima mofetilmikofenolat dokazane teratogene učinke pri podganah in kuncih, se CellCept tablet ne ne sme zdrobiti.
Musculoskeletal pain such as myalgia, and neck and back pain were also very commonly reported. 
Zelo pogosto so poročali tudi o mišično-skeletnih bolečinah, kot so mialgija ter bolečine v vratu in hrbtu.